You are here: Industry Insights > Lava

News List

ProBioGen and LAVA Therapeutics sign cell line development agreement cphi-online
June 24, 2021
The agreement marks the second cell line development collaboration between the two companies
ProBioGen, LAVA to Develop Cell Lines for Bispecific Candidate contractpharma
June 23, 2021
ProBioGen will conduct cell line development of a novel gamma-delta bsTCE using its CHO.RiGHT expression platform.
ProBioGen and LAVA Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific b3cnewswire
June 23, 2021
ProBioGen and LAVA Therapeutics N.V. announced the closing of a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA's pipeline.
Sirtex Medical and BlackSwan Vascular, Inc. announce first patient enrolled in pivotal LAVA Study prnasia
April 20, 2021
Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies, and BlackSwan Vascular, Inc. (BlackSwan), a Bay Area-based private company developing groundbreaking therapies in endovascular embolization, announced that the first ...
ProBioGen and Lava Therapeutics Sign Cell Line Development and GMP Manufacturing Agreement for Novel Bispecific Molecule b3cnewswire
January 16, 2020
ProBioGen AG and Lava Therapeutics B.V. announced the closing of a cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate.